JAK1 and colorectal carcinoma: In addition, we included JAK1 Glu890 gRNA, which was unusual as it scored in the proliferation screens but not the FACS screens (Figure 2G), and the Trp690∗ gRNA as a control; predicted to generate a nonsense mutation observed in a CRC patient that failed to respond to ICB.6